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Abstract: The properties of mesenchymal stem cells (MSCs), especially their self-renewal and ability
to differentiate into different cell lines, are widely discussed. Considering the fact that MSCs isolated
from perinatal tissues reveal higher differentiation capacity than most adult MSCs, we examined
mesenchymal stem cells isolated from Wharton’s jelly of umbilical cord (WJ-MSCs) in terms of
pluripotency markers expression. Our studies showed that WJ-MSCs express some pluripotency
markers—such as NANOG, OCT-4, and SSEA-4—but in comparison to iPS cells expression level is
significantly lower. The level of expression can be raised under hypoxic conditions. Despite their
high proliferation potential and ability to differentiate into different cells type, WJ-MSCs do not form
tumors in vivo, the major caveat of iPS cells. Owing to their biological properties, high plasticity,
proliferation capacity, and ease of isolation and culture, WJ-MSCs are turning out to be a promising
tool of modern regenerative medicine.
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1. Introduction
In general, the ‘stemness’ of cells can be defined as the most primitive cell state that combines two
inseparable properties: the ability of self-renewal and the ability to differentiate. More accurately, stem
cells (SCs) can generate daughter cells that are identical to their mother cells (self-renewal), as well as
progenitor/precursor cells with more restricted potential (differentiation) [1–4].
The maintenance of stemness state requires presence of set of distinctive factors that are expressed
in the cells. The transcription factors NANOG and OCT-4 are considered essential for maintaining the
state of stem cell pluripotency [2,5–10]. NANOG (the name derives from Tìr na nÒg, the mythical
Celtic land of youth) described by Chambers et al. 2003 and Mitsui et al. 2003 in mouse embryonic stem
cells (ESCs) is recognized as the main factor responsible for stem cell self-renewal processes as well
as their pluripotent nature [11–13]. Overexpression of this protein in embryonic cells increases their
proliferative activity as well as maintains them in an undifferentiated state. OCT-4 (Octamer-binding
transcription factor-3/4) is present primarily in early embryos where it plays a key role in the regulation
of pluripotency and stem cell differentiation processes by regulation of other genes’ expression [1,2,9].
Mesenchymal stem cells (MSCs) are a type of multipotent stem cell that are located in many adult
and fetal tissues. Apart from bone marrow, they have been identified and isolated from adipose tissue,
synovium, skin, skeletal muscle, dental pulp, umbilical cord, placenta and other tissues, peripheral
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blood, cornea and retina, liver, and pancreas [14,15]. Some cell characteristics—such as the expression
of specific markers, production of secretomes (cytokines, trophic factors etc.) or exosomes (mRNA,
siRNA etc.), and potential to proliferate or differentiate—may differ depending on the MSCs source
tissue [16–20]. That is why MSCs from various sources are being tested for availability, ease of
separation, in vitro culture requirements and potential clinical applications [15,17,18,21–23]. Due to
these criteria, umbilical cord mesenchymal stem cells have earned a great attention. Wharton’s jelly
mesenchymal stem cells (WJ-MSCs) show the minimal criteria outlined by the International Society
of Cellular Therapy: they adhere to plastic in standard culture conditions, display fibroblast-like
morphology, have tri-lineage differentiation potential (they are able to differentiate into adipocytes,
chondrocytes and osteoblasts), and express specific surface antigens. Populations of the WJ-MSCs
express specific mesenchymal markers such as CD90, CD105, and CD73. The cells also reveal high level
of adhesion receptors—integrin β1 (CD29) and hyaluronan receptor—CD44. Furthermore, WJ-MSCs
are negative for hematopoietic and endothelial antigens: CD45, CD3, and CD34 [3,4,24].
WJ-MSCs might be advantageous for cell-based therapy because of their high self-renewal capacity
in vitro, high plasticity, low immunogenicity, and immunomodulatory properties [25].
Induced pluripotent stem cells (iPS) are obtained by gene reprogramming techniques from adult,
differentiated somatic cells (most often from fibroblasts). After induced expression of pluripotency
transcription factors (OCT-4, SOX2, KLF4, and C-MYC), they become pluripotent. Their pluripotency
is confirmed by expression of the pluripotency markers OCT-4, NANOG, SOX2, SSEA1, SSEA3, SSEA4,
TRA1-60, TRA1-81, ability to form teratomas in vivo, and similarity with ESCs [21,26–28].
Fetal-tissue-derived MSCs exhibit some unique properties—such as ease of isolation and culture,
immunomodulatory capacity, ability to self-regenerate and high proliferation rate, differentiation
into several cell lineages, and lack of ethical problems—that make them the most promising tool in
cell-based therapy. Since it is considered that MSCs derived from fetal tissues are more potent than
from adult tissues, the main goal of the current study was to analyze the pluripotency of mesenchymal
stem cells isolated from Wharton’s jelly. Additionally, we have compared potency of WJ-MSCs with
reference to iPS as cells of well-defined pluripotent properties. It should be noted that the oxygen
concentration is one of the key factors affecting metabolism, proliferation capacity, and phenotype
of the cells [29–34]. Since hypoxia is the most similar to the physiological conditions occurring in
living organisms, we decided to examine WJ-MSCs cultured both in normoxic and hypoxic conditions.
This approach allows for better understanding biological properties of WJ-MSCs.
2. Results
2.1. Characterization of WJ-MSCs
Three different WJ-MSCs lines were cultured in vitro under normoxic and hypoxic conditions.
No significant differences were observed at both conditions (Figure 1A–C).
Cytometric analysis confirmed the presence of WJ-MSCs specific markers characteristic for
MSCs—namely CD73, CD90, and CD105—and a lack of expression for CD3 and CD45 antigens
(Figure 1D,E). This data confirms the homogeneity of the cells’ populations. It should be noted that
WJ-MSCs cultured under standard conditions and with low partial pressure of oxygen express the
aforementioned markers at similar level. There are also no significant differences in expression level of
investigated markers between different WJ-MSCs lines (Figure 1E).
Comparative analysis of transcriptome of investigated WJ-MSC’s population revealed a similarity
of genes profile between three samples. However, the expression data showed that WJ-MSCs 2 and
WJ-MSCs 3 are more similar compared to WJ-MSCs 1 (Figure 1F).
The genes depicted in Figure 1F were chosen based on the biggest differences and the highest
similarities between the three WJ-MSCs cell lines characterized. Genes with the highest expression
(Figure 1G, yellow), with medium expression (Figure 1G, orange) and with the lowest expression
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(Figure 1G, red) in all three lines of WJ-MSCs are shown. Genes with different expression between
tested WJ-MSCs lines are marked in blue color.
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Figure 1. (A–C)—The cultures of WJ-MSCs, fifth passage. The cells grow in a monolayer, show 
adherent properties and fibroblast-like morphology; Morphology of cells cultured in (A–C)—
normoxia—magnification 100×, white bars correspond to 50 µm. (D)—Flow cytometry analysis of 
surface markers expression of WJ-MSCs. The WJ-MSCs were labelled with anti-CD3-FITC and anti-
CD45-FITC antibodies (negative markers) and anti-CD73-PE, anti-CD90-PE, anti-CD105-PE 
antibodies (positive markers), and analyzed by flow cytometry. (D)—Representative histograms 
showing expression of set of markers for WJ-MSCs (detailed analysis presented in the table—(E). (F)—
a heatmap showing the transcription profile of investigated WJ-MSCs. (G)—transcripts of selected 
genes expressed in the WJ-MSCs. The colors of the circles correspond to the colors on the heatmap 
(F): yellow—high expression; orange—medium expression; red—low expression; triangle—genes 
with different expression level. 
2.2. Pluripotency Marker Expression in Normoxic and Hypoxic Conditions 
The analysis of OCT-4 and NANOG expression at the mRNA level by real-time qPCR 
demonstrated lower level of the mRNA expression in WJ-MSCs under both low and high oxygen 
concentrations compared to iPS cells (Figure 2A,B). However, our data confirm previous results that, 
at the mRNA level, the expression of NANOG under hypoxic conditions is increased (Figure 2A). 
Intracellular analysis of NANOG and OCT-4 using flow cytometry revealed low expression or 
no expression of both proteins in WJ-MSCs (Figure 2C,D). However, hypoxic conditions stimulated 
Figure 1. (A–C)—The cultures of WJ-MSCs, fifth passage. The cells grow in a monolayer,
show adherent properties and fibroblast-like morphology; Morphology of cells cultured in
(A–C)—normoxia—magnification 100×, white bars correspond to 50 µm. (D)—Flow cytometry
analysis of surface markers expression of WJ-MSCs. The WJ-MSCs were labelled with anti-CD3-FITC
and anti-CD45-FITC antibodies (negative markers) and anti-CD73-PE, anti-CD90-PE, anti-CD105-PE
antibodies (positive markers), and analyzed by flow cytometry. (D)—Representative histograms
showing expression of set of markers for WJ-MSCs (detailed analysis presented in the table—(E). (F)—a
heatmap showing the transcription profile of investigated WJ-MSCs. (G)—transcripts of selected genes
expressed in the WJ-MSCs. The colors of the circles correspond to the colors on the heatmap (F):
yellow—high expression; orange—medium expression; red—low expression; triangle—genes with
different expression level.
2.2. Pluripotency Marker Expression in Normoxic and Hypoxic Conditions
The analysis of OCT-4 and NANOG expression at the mRNA level by real-time qPCR demonstrated
lower level of the mRNA expression in WJ-MSCs under both low and high oxygen concentrations
compared to iPS cells (Figure 2A,B). However, our data confirm previous results that, at the mRNA
level, the expression of NANOG under hypoxic conditions is increased (Figure 2A).
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concentration (Figure 2E). At the same time iPS cells showed strong presence of SSEA-3, SSEA-4, and 
TRA 1-60 (Figure 2C,E). The expression level of surface markers has been estimated in reference to 
appropriate isotype control. 
 
Figure 2. Pluripotency markers expression on mRNA (A,B) and protein level (C,D) determined with 
RT-qPCR and flow cytometry (intracellular staining) respectively. (A,B)—Comparison of NANOG 
and OCT-4 relative expression level by RT-qPCR in WJ-MSCs and iPS. iPS exhibits relatively very 
high expression compared to WJ-MSCs. Note that hypoxia promotes NANOG expression in WJ-
MSCs. Results are presented as means ± standard error, * p ≤ 0.0001 (A); * p ≤ 0.0006 (B). (C,D)—
expression of NANOG and OCT-4 examined using intracellular staining and flow cytometry analysis. 
The iPS show a high expression of NANOG and OCT-4. In the case of WJ-MSCs the visible higher 
expression of NANOG was noticed in hypoxic conditions. H—hypoxia, N—normoxia. (E)—
Expression level of pluripotency markers: SSEA-3, SSEA-4, TRA 1-60 (antibody labelling and flow 
Figure 2. Pluripotency arkers expression on R A (A,B) and protein level (C, ) deter ined ith
RT-qPCR and flow cytometry (intracellular staining) respectively. (A,B)—Comparison of NANOG and
OCT-4 relative expression level by RT-qPCR in WJ-MSCs and iPS. iPS exhibits relatively very high
expression compared to WJ-MSCs. Note that hypoxia promotes NANOG expression in WJ-MSCs.
Results are presented as means ± standard error, * p ≤ 0.0001 (A); * p ≤ 0.0006 (B). (C,D)—expression
of NANOG and OCT-4 examined using intracellular staining and flow cytometry analysis. The iPS
show a high expression of NANOG and OCT-4. In the case of WJ-MSCs the visible higher expression
of NANOG was noticed in hypoxic conditions. H—hypoxia, N—normoxia. (E)—Expression level of
pluripotency markers: SSEA-3, SSEA-4, TRA 1-60 (antibody labelling and flow cytometric analysis).
Note that iPS exhibit high expression all of examined pluripotency markers whereas on WJ-MSCs only
SSEA-4 is expressed. H—hypoxia; N—normoxia.
Intracellular analysis of NANOG and OCT-4 using flow cytometry revealed low expression or
no expression of both proteins in WJ-MSCs (Figure 2C,D). However, hypoxic conditions stimulated
NANOG expression in larger populations of cells (Figure 2D). The presence of OCT-4 did not change
or increase only slightly. As expected, more than 90% of the iPS cells express both factors (Figure 2D).
The genetic modification in case of WJ-MSCs Luc+ has no influences on NANOG and OCT-4 expression
(Figure 3D,E).
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OCT-4 (transcription factors) and SSEA-3, SSEA-4, TRA 1-60 (surface markers) in iPS (A) and WJ-
MSCs (B,C). (D,E)—expression of NANOG and OCT-4 in WJ-MSC Luc+ (the modified cell line 
expressing luciferase gene). Nuclear staining–Hoechst 33342: blue; NANOG and OCT-4 –Alexa Fluor 
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2.3. In Vivo Safety of WJ-MSCs—Tumorogenicity Assay 
In order to check the tumorigenicity of WJ-MSCs, they were marked with Luciferase, cultured 
in normoxia and hypoxia and injected subcutaneously into immunodeficient NOD-SCID mice. Mice 
were observed for as long as 3 months and imaged with the Optical Preclinical Imaging System. 
Figure 3. Immunofluorescence staining demonstrate distribution of pluripotency markers: NANOG,
OCT-4 (transcription factors) and SSEA-3, SSEA-4, TRA 1-60 (surface markers) in iPS (A) and WJ-MSCs
(B,C). (D,E)—expression of NANOG and OCT-4 in WJ-MSC Luc+ (the modified cell line expressing
luciferase gene). Nuclear staining–Hoechst 33342: blue; NANOG and OCT-4 –Alexa Fluor 555: red;
SSEA-4-FITC: green; TRA 1-60-PE, SSEA-3-PE: red. (A–E)—Florescence microscope, (A) magnification
×150, insets- magnification ×100; (B–E)—magnification ×100, insets—magnification ×80.
The three WJ-MSCs preparations were analyzed using Lyoplate screening panels. The WJ-MSCs
did not express stage-specific embryonic antigens 3 (SSEA-3) and tumor rejection antigen (TRA 1-60)
markers but they expressed SSEA-4 at relatively high level in all 3 lines of WJ-MSCs (Figure 2E). The
level of SSEA-4 expression was slightly decreased by culture of WJ-MSCs n 5% of oxygen concentrat on.
The expr ssion of SSEA-3 and TRA 1-60 was not influence by low oxygen o centration (Figure 2E).
At the same time iPS cells showed strong presence of SSEA-3, SSEA-4, and TRA 1-60 (Figure 2C,E).
The expression level of surface markers has been estimated in reference to appropriate isotype control.
The flow cytometry results were confirmed by additional immunocytochemical staining (Figure 3).
As expected, iPS cells showed high expression of all the pluripotency markers (Figure 3A). SSEA-4
was detected in WJ-MSCs cultured at both 5% and 21% oxygen concentrations (Figure 3B). However,
when WJ-MSCs were cultured in low oxygen concentrations, expression of NANOG and OCT-4 was
observed (Figure 3C).
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2.3. In Vivo Safety of WJ-MSCs—Tumorogenicity Assay
In order to check the tumorigenicity of WJ-MSCs, they were marked with Luciferase, cultured in
normoxia and hypoxia and injected subcutaneously into immunodeficient NOD-SCID mice. Mice were
observed for as long as 3 months and imaged with the Optical Preclinical Imaging System. During
the experiment, gradual loss of the luminescence signal was observed in both groups. After 30 days,
the luminescence signal was lost in the normoxia group (Figure 4A–C) but in hypoxia group it was still
observable until day 37 (Figure 4E–G). After 90 days luminescence signal from both injected groups
was not detected (Figure 4D,H). During the experiment, no deterioration in the health of mice was
observed, as well as noticeable changes in the site and area of the implanted WJ-MSCs. Thus, after
transplantation of WJ-MSCs, there was no tumorigenic proliferation observed. At the same time,
in group consisted of mice injected with iPS Luc+ cells the signal of luminescence slightly decreased
after a few days (Figure 4J) but on day 24 after administration, an increase of the luminescence signal
was observed (Figure 4K) which persisted until day 30 when mice were killed (Figure 4L). Tumors
from mice in the iPS Luc+ group were isolated and fixed (Figure 4M). Luminescence imaging analysis
of the tumors confirmed their derivation from Luc positive cells (Figure 4N) and histopathological
analysis revealed very characteristic morphology of teratomas that included tissues from all germ
layers (Figure 4O).
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Figure 4. NOD-SCID mice injected subcutaneo l it ce ls transduced wi th vector transferring
the luciferas gene (Luc): WJ-MSCs Luc+ ( i S Luc+ (I–L). The modified WJ-MSCs were
cultured in two oxygen conditions: J- SCs Luc+ normoxia (A–D) and WJ-MSCs Luc+ hypoxia
(E–H). The presence of injected cells was observed after luciferin administration by measuring the
bioluminescence signal. After 30 days, in mice with normoxia, WJ-MSCs Luc+ signal was not detectable
(C), whereas in mice with WJ-MSCs Luc+ hypoxia signal persisted. In mice with iPS Luc+ luminescence
signal increased as a result of tumor development (G,H). 30 days after transplantation the tumors
were isolated (M,N) and subsequently analyzed with hematoxylin and eosin staining (O). (O)—Light
microscopy, magnification ×100, white bar corresponds to 150µm. Black asterisks—control mice
without injected cells.
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3. Discussion
The specific properties of the mesenchymal stem cells, particularly their ability to differentiate
and their paracrine activity, are of the special interest in terms of their therapeutic effects. In preclinical
and clinical studies, their beneficial effect has been demonstrated in the treatment of many diseases:
cardiovascular diseases [35], neurodegenerative diseases [36], immune-mediated diseases [37], etc.
The MSCs are commonly classified as multipotent, but they express a relatively low level of pluripotent
markers characteristic for embryonic stem cells (ESCs) and iPS cells. It has been demonstrated that
pluripotent cells express a unique set of factors necessary for the maintenance of stemness—namely
OCT-4, NANOG, and SOX2 [2,5–9]. As described previously, these transcription factors are involved
in regulation of the pluripotency, self-renewal, and proliferation [7]. OCT-4 is necessary to initiate
embryonic development of mammals and is essential for the formation of embryos’ inner cell mass
and ESCs maintenance [8]. SOX2 regulates expression of OCT-4 and maintains the pluripotent state of
ESCs, whereas NANOG is required for the maintenance of undifferentiated state and self-renewal of
stem cells [7]. The same factors are also responsible for the pluripotent state of iPS cells.
Our studies have shown that WJ-MSCs express pluripotency markers: NANOG, OCT-4,
and SSEA-4. Our results are consistent with those reported by other investigators who also described
the presence of OCT-4, SOX2, and NANOG in mesenchymal stem cells isolated from human umbilical
cord [10,24,38]. However, our data show that WJ-MSCs exhibit much lower expression levels of these
markers in comparison to human iPS cells. Similar results were obtained for ESCs and WJ-MSCs by
Gao et al. They demonstrated significant expression of NANOG, SSEA-4, and SOX2, but the level of
expression was relatively lower in WJ-MSCs than in human ESCs [10].
The analysis of transcriptome profiles of all examined cells confirmed that investigated WJ-MSCs
are highly homogeneous population of cells. In the present study we selected for analysis group of
genes with the highest and the lowest expression. Our results revealed that in group of genes with
the highest expression, there are no genes known as pluripotency markers (OCT-4, NANOG, SOX2,
SSEA-1, SSEA-3, SSEA-4, TRA1-60, TRA1-81). These results may explain why WJ-MSCs do not induce
teratomas when transplanted into immunodeficient mice.
The culture conditions are very important issue that should be considered during examination
of properties of the cells. Microenvironment, including oxygen conditions, is one of the main factors
affecting metabolism, angiogenesis, proliferation, differentiation, and stemness of cells [29–34,39].
In this study we have observed strong influence of hypoxic conditions on expression of pluripotency
markers, especially NANOG, at both mRNA and protein level. Our results are in partial agreement
with data presented by Drela and colleagues, who showed that WJ-MSCs cultured in 21% O2 do not
express OCT-4, NANOG, SOX2, and REX 1 by immunocytochemistry staining and RT-PCR analysis.
However, they also showed that 5% oxygen promotes expression of these genes [31]. This discrepancy
may be due to WJ-MSCs isolation protocol and/or culture conditions. Apart from its effect on expression
of pluripotency factors, hypoxia also affects proliferation rate of WJ-MSCs. Nekanti and colleagues [39]
showed that WJ-MSCs under hypoxic conditions have higher proliferation rate and shorter mean
population doubling time compared to WJ-MSCs cultured in normoxia. Our observations did not
confirm that, since we observed only slightly higher proliferation rate of WJ-MSCs in hypoxia than in
normoxia, which can be explained by the expression of NANOG already in normoxic conditions.
ESCs and iPS, that express the pluripotency genes form teratomas what proves their pluripotent
character [40]. Considering the fact that WJ-MSCs express some of the pluripotency genes, we also
examined them in terms of tumorigenicity. Since the expression of OCT-4 and NANOG increased
in low oxygen conditions we transplanted WJ-MSCs cultured in normoxic or hypoxic environments.
Interestingly, we did not observe any tumor development even after 90 days after transplantation,
despite the fact that these cells display intermediate potency between pluripotent stem cells and adult
MSCs [17,41]. iPS cells injected at the same time generated teratomas in vivo three weeks after injection.
These results clearly show that WJ-MSCs are not tumorigenic despite expression of pluripotent genes.
Thus, the cell-based therapy involving WJ-MSCs seems to be safe from that standpoint.
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It has been proved that stem cells may migrate and engraft in the site of injury. Their repair
mechanism is demonstrated by the secretion of many factors including cytokines and extracellular
vesicles that affect tissue regeneration. Therefore, many studies focus on cell survival after
transplantation. Toma et al. (2002) demonstrated the presence of transplanted MSCs in the mice hearts
for up to 4 days [42]. In the porcine model of myocardial ischemia, it was observed that the injected
cells are able to survive 10 days after administration [43]. McGinley et al., 2013 have reported that
MSCs were detectable in an infracted rat heart at a very low level 28 days after transplantation [44].
Our studies have shown that transplanted WJ-MSCs cultured under hypoxia conditions are detectable
at 37 days after injection. The survival time of cells that were normally grown under normoxia
conditions is clearly shorter what does not exclude their regenerative properties. It is commonly
known that stem cells derived from adult tissues exhibit much lower potency than embryonic stem
cells [45]. Interestingly, WJ-MSCs derived from fetal tissue (human umbilical cord) not only possess
mesenchymal stem cells properties, but also some features characteristic for ESCs [22,23,46–48]. Since
it is hypothesized that WJ-MSCs are formed within the mucous connective tissue of the umbilical
cord (Wharton’s jelly) in the early days of embryonic development and then reside there during
gestation [49], this may explain their embryonic character and greater potential than MSCs’ derived
from adult sources.
It is believed that MSCs are pluripotent/multipotent, thus able to differentiate into three germ layer
cell types [6,50,51]. They easily differentiate into adipocytes, chondrocytes and osteocytes, but there
are also reports about differentiation of MSCs into other germ layer derivatives such as neurons
(derived from ectoderm) [51] and hepatocytes (originated in endoderm). However, non-mesodermal
differentiation of MSCs is still discussed because of insufficient in vivo evidence [52]. Since we were
unable to growth teratomas from WJ-MSCs, our data exclude the pluripotency-based phenotypic
differentiation characterization of WJ-MSCs despite expression of OCT-4, NANOG and SOX2.
4. Materials and Methods
4.1. Collection, Isolation, and Expansion of WJ-MSCs
The umbilical cords were collected from three patients after Caesarean sections after parents’
consent. After washing with phosphate-buffered saline (PBS) solution supplemented with
antibiotic-antimycotic solution, umbilical cords were cut into small (5 mm) pieces. Around 50 small
slices of umbilical cord were put onto the plastic flask. Explants were cultured with growth medium
for mesenchymal stem cells (DMEM Low Glucose, Biowest, USA), supplemented with platelet lysate
in a standard culture conditions under 21% of O2 and 5% of CO2 at 37 ◦C and hypoxic condition under
5% of O2 and 5% of CO2 at 37 ◦C. After 7 days, the explants were removed, and the cells were passaged
using Accutase cell detachment solution (BioLegend, USA). After reaching the appropriate number of
cells, WJ-MSCs were cultured in the Quantum Cell Expansion Bioreactor (Therumo BCT), then frozen
and thawed for analysis at passage 5. Isolated colonies of cells displayed fibroblast-like morphology.
Inverted light microscope Olympus IX70 with phase contrast optics equipped with a Canon EOS1100D
digital photo camera was used for routine observation, analysis, and documentation of the MSCs at a
morphological level.
The three cell lines (WJ-MSCs 1, WJ-MSCs 2, WJ-MSCs 3) examined in this study have been
isolated from three umbilical cords (from three different donors).
The cells were obtained as part of the project STRATEGMED II (agreement no.
Strategmed2/265761/10/NCBR/2015).
4.2. iPS Cell Cultures
Protein induced pluripotent stem cells (piPS, System Biosciences, USA), were cultured on
Gelatin (Sigma-Aldrich, St. Louis, MO, USA) coated dishes with feeder layer of mitomycin C
(Sigma-Aldrich, USA) inactivated mouse embryonic fibroblasts (MEFs) in serum-free iPS medium
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DMEM/F12 supplemented with 20% KSR, 2 mM GLUTAMAX, 100 µM non-essential amino acids,
100 U/mL/100 µg/mL Penicillin/Streptomycin, 10 ng/mL bFGF (all from ThermoFisher Scientific,
USA) and 100 µM -mercaptoethanol (Sigma-Aldrich). The medium was changed every day. When
the culture reached about 80% confluence, iPS cells were subcultured with Accutase (Lonza, Basel,
Switzerland) in proportion 1:4–1:10 and seeded onto fresh feeder layer in presence of 10 µM ROCK
inhibitor Y-27632 (Sigma-Aldrich). For immunocytochemical stainings, iPS cells were cultured in
feeder-free conditions on growth factor-reduced Matrigel (Corning, New York, NY, USA) coated dishes
in MEF-conditioned iPS medium. MEFs were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
4.5 g/L glucose; Lonza), supplemented with 10% v/v FBS, 2 mM L-glutamine and 100 U/mL/100 µg/mL
Penicillin/Streptomycin antibiotics solution (all from ThermoFisher Scientific, Waltham, MA, USA).
4.3. Flow Cytometry Analysis
4.3.1. Immunophenotype Analysis
Expression of specific surface antigens outlined for mesenchymal stem cells by the International
Society of Cellular Therapy on WJ-MSCs was tested using flow cytometry technique. The cells were
harvested with Accutase cell detachment solution (BioLegend, San Diego, CA, USA). The WJ-MSCs
were incubated with fluorochrome-conjugated (fluorescein isothiocyanate-FITC and phycoerythrin-PE)
antibodies against CD73, CD90, CD105, CD3, and CD45 (Becton Dickinson, Franklin Lakes, NJ, USA)
for 30 min. at 4 ◦C in darkness. Corresponding isotype antibodies were used as the control to exclude
non-specific binding. The results were analyzed using Attune NxT Software v2.2 on Attune Nxt Flow
cytometer (Thermo Fisher Scientific).
4.3.2. Lyoplate Screening Panel
The expression level of adhesion molecules was evaluated using Lyoplate technology from BD
(Becton Dickinson). The WJ-MSCs were stained with monoclonal primary antibodies and, subsequently
with secondary antibodies conjugated with fluorophore against selected surface antigens from a
Lyoplate screening panel. The procedure was carried out according to manufacturer’s instruction. The
cells were acquired using Attune Nxt Flow Cytometer equipped with autosampler, that allows fully
automated sample acquisition from 96-well plates. A total of 10,000 viable cells (events) were analyzed
per sample. The data were analyzed and presented as standard histograms.
4.3.3. Expression of Pluripotent Markers
WJ-MSCs were stained with fluorescein-isothiocyanate (FITC) and phycoerythrin (PE) conjugated
primary antibodies against pluripotency markers SSEA-3, SSEA-4, TRA 1-60 (Becton Dickinson) for
30 min at 4 ◦C. Appropriate PE-conjugated or FITC-conjugated antibodies were used as an isotype
control. The fluorescence intensity of the cells was evaluated by flow cytometry Attune Nxt Flow
Cytometer. Data was analyzed using Attune NxT Software v2.2.
4.3.4. Intracellular Staining
Harvested cells were washed with PBS and fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich)
for 15 min. Next, the cells were washed and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for
20 min at room temperature. The cells were stained with primary antibodies anti-OCT-4 (1:100, Merck,
Darmstadt, Germany) and anti-NANOG (1:500, Merck) and incubated for 1 h at RT. Then, the pellet of
cells was stained with appropriate secondary antibody conjugated with Alexa Fluor-488 (1:200, Life
Technologies, Carlsbad, CA, USA) for 60 min. The results were collected by flow cytometer Attune Nxt
Cytometer and data was analyzed using Attune NxT Software v2.2.
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4.4. Immunocytochemistry
The immunocytofluorescence staining method was used to determine the expression of the
markers of particular cell types at the protein level. The WJ-MSCs and modified WJ-MSCs Luc+ were
plated on 24-well plates on glass coverslips. When the cells were ready for staining, the culture medium
was drained and the cells were fixed with 4% paraformaldehyde for 20 min at room temperature.
The next step was permeabilization of cell membranes with 0.1% Triton X-100 solution in PBS (5 min
at room temperature). After three washes with PBS, the sites of non-specific antibody binding were
blocked using a 3% BSA solution (in PBS) for 30 min at room temperature. The cells were then incubated
overnight at 4 ◦C with the appropriate primary antibody diluted in 3% BSA. The following day, the
cells were washed three times with PBS and incubated at room temperature in the dark for 1 h with the
appropriate secondary antibody diluted in 3% BSA and with Hoechst 33342 (nucleic acid binding) dye.
The unbound antibody was then washed three times with PBS. Stained cells were compared to isotype
control to confirm the specificity of staining and to distinguish staining from autofluorescence of cells.
4.5. Real-Time PCR (qPCR), RNA Isolation, Reverse Transcription
Total RNA was isolated using RNA GeneMATRIX Universal RNA Purification Kit (EURx, Gdańsk,
Poland) according to the manufacturer’s instruction. Reverse transcription was performed using
commercial reagent kit MMLV Reverse Transcriptase (Promega, Madison, WI, USA). The expression of
the pluripotency factors OCT-4 and NANOG at the mRNA level was verified by qPCR using SybrGreen
(EURx) and designed primers (Table 1) and blank qPCR Master Mix reagent (EURx, Poland). The mRNA
expression level for all samples were normalized to the housekeeping gene GAPDH transcript as a
reference gene. Levels of mRNA expression were determined with the 2−∆∆Ct method. The real-time
qPCR was performed with the Applied Biosystems QuantStudio 7 Flex real-time PCR system.
Table 1. Primer sequences used for real-time PCR genes expression analysis.
Gene Forward Primer Reverse Primer
OCT-4 ATGGCGGGACACCTGGCTT GGGAGAGCCCAGAGTGGTGACG
NANOG TGAACCTCAGCTACAAACAG TGGTGGTAGGAAGAGTAAAG
GAPDH CAAAGTTGTCATGGATGACC CCATGGAGAAGGCTGGGG
4.6. RNA Preparation for Whole-Genome Sequencing
Total RNA was extracted from WJ-MSCs samples using QIAGEN RNeasy Mini-Kit (QIAGEN,
Hilden, Germany). RNA from all samples was run on an Agilent TapeStation System (Agilent
Technologies, Santa Clara, CA, USA) to assess quality, and to estimate RNA concentrations, RNA was
quantitated by Promega QuantiFluor Dye System on Quantus Fluorometer (Promega).
4.7. Gene Expression Quantification
300 ng of total RNA was used to generate biotinylated cRNA using the TargetAmp-Nano Labeling
Kit for Illumina Expression BeadChip (Epicentre-an Illumina Company, Madison, WI, USA) which
was fragmented and hybridized to an Illumina Whole Genome Expression Chip, HumanHT-12
v3.0. BeadChips were then washed and stained and subsequently scanned to obtain fluorescence
intensities. Expression profiles were generated by hybridizing 750 ng of cRNA to Illumina HumanHT-12
v3.0 BeadChips according to Illumina whole-genome gene expression direct hybridization assay
guide (Illumina).
4.8. Tumorogencity Assay (In Vivo)
Determination of the safety of the use of WJ-MSCs based therapy was performed with
immunocompromised NOD-SCID mice. The experiment was conducted in two independent groups
consisting of four mice per group. The groups got WJ-MSCs cultured in hypoxia and normoxia
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conditions respectively. Each mouse of two groups was injected subcutaneously with 2x106 cells
transduced with the vector harboring the luciferase gene (Luc+). As a positive control, mice were
injected with 2x106 iPS Luc+. The luminescence signal was measured biweekly in both groups until
the signal was lost (optical preclinical imaging system/for small animals—Ami). Tumor formation
in mice was monitored for 3 months. After this time, the luminescence signal was measured in the
WJ-MSCs groups. Mice from WJ-MSCs groups were sacrificed after 3 months. In the control group
after the appearance of tumors, the mice were sacrificed and the tumors were excised. Fixed tissues
were imbedded in paraffin, cut, stained with hematoxylin/eosin and analyzed histopathologically.
Each of the experiments was repeated three times in order to authenticate the obtained results.
The experiments on animals have been carried out in accordance with the “Guidelines for the
Care and Use of Laboratory Animals”. The protocol was approved by the Second Local Institutional
Animal Care and Use Committee (IACUC) in Krakow by decision number 278/2015 on 15 December
2015 and 162/2015 on 24 June 2015.
4.9. Statistical Analysis
Statistical analysis was performed with GraphPad Prism 7 software. Data are shown as ± standard
error of the mean. Statistical comparisons were evaluated using an analysis of ANOVA test with
post-hoc Dunnett’s test, with p ≤ 0.0001 for NANOG and p ≤ 0.0006 for OCT-4 considered statistically
significant difference.
5. Conclusions
WJ-MSCs show all properties characteristic for mesenchymal stem cells outlined by the
International Society for Cellular Therapy. Moreover, they also express some pluripotency markers,
but compared to iPS cells, the expression of NANOG, OCT-4, and SSEA-4 is lower and SSEA-3 and
TRA 1-60 do not occur. The better understanding of plasticity/potential of MSCs is very important in
the context of their use in therapeutic purposes. The advantages of WJ-MSCs in clinical application
include ease and high yield of isolation, proliferation, and immunomodulation. Furthermore, they are
exempt from ethical implications of ESCs and their acquisition does not pose a risk of complications
for the donor [4,53,54]. Importantly, despite their high proliferation potential and pluripotent gene
expression, they do not form teratomas in vivo also after culture in hypoxic conditions. Thus, our data
provide further evidence on the safe use of WJ-MSCs in clinical settings.
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